Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Addressing PIRA and PROMs in clinical practice

Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and President of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), describes the main challenges associated with the management of multiple sclerosis (MS) in clinical practice. Treatment strategies addressing progression independent of relapse activity (PIRA) remain an unmet need contributing to one of the biggest challenges in the MS space, which is the treatment of MS progression. The importance of including patients in treatment decision-making has been recognized by many clinicians. However, the incorporation of patient-reported outcome measures (PROMs) into the treatment algorithm has been challenging, but eHealth and digital medicine strategies can be key in understanding and incorporating those measures into clinical practice. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


M Tintore has received compensation for:
Consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio, Viatris and Teva Pharmaceuticals.
Receipt grants and research supports from Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000, Biogen-Idec, Novartis.